Anebulo Pharmaceuticals (ANEB) AI Stock Analysis

• Market Cap: $97.78M
• Dividend Yield: N/A
• Average Volume (3M): 791.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: N/A
• EPS Growth: 26.34%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 41,084,732
• 10 Day Avg. Volume: 169,076
• 30 Day Avg. Volume: 791,848
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -5.52
• 1Y Price Target: $3.00
• Price Target Upside: 25.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 35 Underperform
• Price Target: ―

Anebulo Pharmaceuticals is struggling financially, with no revenue generation and consistent losses. The technical indicators reflect a bearish trend, with the stock trading below key moving averages. Valuation metrics are weak due to negative earnings. While the balance sheet is strong with no debt, the heavy reliance on financing activities poses a risk. Investors should be cautious and consider the company's ability to achieve profitability and secure future funding.

Positive Factors

FDA Support

The company received positive reinforcement from the US FDA related to an unmet need for a treatment for children exposed to cannabis toxicity.

Privatization Plan

Board approves plan to go private at a 91% premium to previous close.

Negative Factors

Price Target Reduction

Analyst is lowering the price target to $3 due to increased share count and reduced valuations for other biotech companies.

Stock Downgrade

Stock rating downgraded to Hold.

Anebulo Pharmaceuticals Business Overview & Revenue Model

Company Description

Anebulo Pharmaceuticals (ANEB) is a clinical-stage biotechnology company focused on developing novel treatments for patients suffering from cannabinoid overdose and substance addiction. The company primarily operates within the pharmaceutical and biotechnology sectors, targeting unmet medical needs related to the growing marijuana and cannabinoid markets. Anebulo's lead product candidate, ANEB-001, is an orally administered small molecule designed to treat acute cannabinoid intoxication.

How the Company Makes Money

Anebulo Pharmaceuticals generates revenue primarily through the development and potential commercialization of its lead product candidate, ANEB-001. As a clinical-stage company, Anebulo's current revenue streams are limited, and it largely relies on funding through public and private investment to support its research and development activities. In the future, the company plans to earn income through licensing agreements, strategic partnerships, and sales of its pharmaceutical products upon receiving regulatory approval. Significant partnerships with larger pharmaceutical companies could also contribute to its revenue by providing milestone payments, royalties, and collaborative research funding.

Anebulo Pharmaceuticals Financial Statement Overview

Summary

Anebulo Pharmaceuticals faces significant financial challenges typical of early-stage biotech companies. With no revenue and consistent losses, the company relies heavily on equity financing to sustain its operations. While the balance sheet is strong due to zero debt, the ongoing cash burn and lack of profitability are major concerns. Investors should be cautious and consider the company's ability to secure future funding and achieve revenue growth.

Income Statement

Anebulo Pharmaceuticals has shown consistent net losses over the years, with no revenue generation. The TTM data shows a net income of -$7.67 million, indicating a lack of profitability. The absence of revenue growth and negative EBIT and EBITDA margins highlight the company's struggle to achieve operational efficiency.

Balance Sheet

The company maintains a strong equity base with zero debt, leading to a favorable debt-to-equity ratio. However, the return on equity remains negative due to continuous losses. The equity ratio is high, indicating reliance on equity for funding, which is common in early-stage biotech firms.

Cash Flow

Anebulo has a negative free cash flow, with the TTM free cash flow being -$6.65 million. The operating cash flow to net income ratio is relatively stable, but the company relies heavily on financing activities to sustain operations. This reliance poses a risk if external funding sources dry up.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-8.05M	-11.78M	5.55K	-30.24M	-173.35K
Net Income	-8.20M	-11.73M	-6.83M	-30.25M	-174.64K
Balance Sheet
Total Assets	4.07M	11.67M	15.58M	21.65M	3.03M
Cash, Cash Equivalents and Short-Term Investments	3.09M	11.25M	14.55M	19.99M	3.02M
Total Debt	0.00	0.00	0.00	0.00	201.29K
Total Liabilities	260.58K	1.07M	512.53K	241.63K	3.20M
Stockholders Equity	3.81M	10.60M	15.07M	21.41M	-171.14K
Cash Flow
Free Cash Flow	-8.09M	-9.68M	-5.44M	-4.87M	-150.77K
Operating Cash Flow	-8.09M	-9.68M	-5.44M	-4.87M	-150.77K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	-62.35K	6.38M	0.00	21.83M	3.18M

Anebulo Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANEB, the sentiment is Positive. The current price of 2.4 is below the 20-day moving average (MA) of 2.56, above the 50-day MA of 1.90, and above the 200-day MA of 1.51, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 52.23 is Neutral, neither overbought nor oversold. The STOCH value of 21.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANEB.

Anebulo Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$18.14B	5.30	-4.00%	3.33%	10.16%	-17.39%
HYPR	54 Neutral	$93.41M	―	-67.86%	―	0.34%	6.20%
ALGS	44 Neutral	$45.74M	―	-87.74%	―	-60.16%	―
ATNM	41 Neutral	$47.11M	―	-130.59%	―	-100.00%	13.14%
VTVT	38 Underperform	$46.29M	―	-203.31%	―	-98.30%	54.90%
ANEB	35 Underperform	$97.78M	―	-83.37%	―	―	26.34%
PRLD	35 Underperform	$47.31M	―	-81.44%	―	―	9.14%